Zacks Research Reduces Earnings Estimates for HealthEquity

Key Points

• Zacks Research has decreased its Q3 2026 earnings per share (EPS) estimate for HealthEquity from $0.74 to $0.71, with a full-year earnings consensus of $2.32 per share.
• Despite the earnings estimate reduction, several analysts have raised their price targets for HealthEquity, with an average target of $119.77 and a consensus rating of "Buy."
• Institutional investors hold a significant stake in HealthEquity, owning approximately 99.55% of the company's stock.

HealthEquity, Inc. (NASDAQ:HQY - Free Report) - Stock analysts at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for HealthEquity in a research note issued on Tuesday, September 23rd. Zacks Research analyst Team now expects that the company will earn $0.71 per share for the quarter, down from their prior forecast of $0.74. The consensus estimate for HealthEquity's current full-year earnings is $2.32 per share. Zacks Research also issued estimates for HealthEquity's Q4 2026 earnings at $0.72 EPS, FY2026 earnings at $3.20 EPS, Q1 2027 earnings at $0.93 EPS, FY2027 earnings at $3.73 EPS, Q1 2028 earnings at $1.02 EPS, Q2 2028 earnings at $1.11 EPS and FY2028 earnings at $4.08 EPS.

Several other equities analysts also recently issued reports on HQY. Royal Bank Of Canada lifted their price target on shares of HealthEquity from $109.00 to $110.00 and gave the company an "outperform" rating in a report on Wednesday, September 3rd. Raymond James Financial reiterated a "strong-buy" rating and issued a $120.00 target price (up previously from $115.00) on shares of HealthEquity in a research note on Tuesday, July 8th. JMP Securities increased their price target on HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a research report on Wednesday, June 4th. Barrington Research reaffirmed an "outperform" rating and set a $125.00 price target on shares of HealthEquity in a report on Friday, August 29th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on HealthEquity from $98.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, June 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $119.77.

HealthEquity Stock Up 2.0%

Shares of NASDAQ:HQY opened at $96.16 on Friday. The company's fifty day moving average is $92.63 and its 200-day moving average is $93.92. The company has a debt-to-equity ratio of 0.47, a quick ratio of 4.23 and a current ratio of 4.23. HealthEquity has a 52 week low of $74.07 and a 52 week high of $116.65. The company has a market capitalization of $8.29 billion, a PE ratio of 58.28, a P/E/G ratio of 1.35 and a beta of 0.50.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Invesco Ltd. raised its stake in shares of HealthEquity by 50.6% during the first quarter. Invesco Ltd. now owns 2,446,198 shares of the company's stock worth $216,171,000 after buying an additional 821,425 shares during the last quarter. Westfield Capital Management Co. LP grew its holdings in HealthEquity by 124.6% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,265,208 shares of the company's stock worth $132,543,000 after acquiring an additional 701,819 shares during the period. Goldman Sachs Group Inc. raised its position in shares of HealthEquity by 1.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,133,166 shares of the company's stock valued at $100,138,000 after acquiring an additional 15,458 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of HealthEquity by 2.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 1,129,115 shares of the company's stock valued at $118,286,000 after purchasing an additional 28,145 shares during the period. Finally, Geneva Capital Management LLC boosted its position in shares of HealthEquity by 6.2% in the 2nd quarter. Geneva Capital Management LLC now owns 1,108,241 shares of the company's stock worth $116,099,000 after purchasing an additional 64,487 shares during the last quarter. Institutional investors own 99.55% of the company's stock.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, EVP Delano Ladd sold 6,000 shares of the stock in a transaction on Friday, September 19th. The stock was sold at an average price of $94.11, for a total value of $564,660.00. Following the transaction, the executive vice president directly owned 79,456 shares in the company, valued at approximately $7,477,604.16. This trade represents a 7.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Henry Fiore sold 1,794 shares of the business's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $101.73, for a total value of $182,503.62. Following the sale, the executive vice president owned 53,225 shares of the company's stock, valued at approximately $5,414,579.25. The trade was a 3.26% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.